Copyright 2003 PR Newswire Association, Inc.
PR Newswire
September 8, 2003, Monday
SECTION: FINANCIAL NEWS
DISTRIBUTION: TO BUSINESS AND MEDICAL EDITORS
LENGTH: 474 words
DATELINE: RESEARCH TRIANGLE PARK, N.C., Sept. 8

Incara Pharmaceuticals Corporation (OTC Bulletin Board: INCR) announced today that its catalytic antioxidant compound, AEOL 10150, has demonstrated efficacy in an animal model of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). John P. Crow, Ph.D., Professor of Pharmacology and Toxicology at the University of Arkansas for Medical Sciences, who conducted the recent experiments, will present the results at the 226th American Chemical Society National Meeting in New York City. Dr. Crow is an invited speaker at a symposium on Redox- and Chelation-based Drugs, a component of the Medicinal Inorganic Chemistry Session to be held on Thursday, September 11, 2003.

Incara Pharmaceuticals Corporation is developing a new class of small molecule catalytic antioxidants that destroy oxygen-derived free radicals, believed to be an important contributor to the pathogenesis of many diseases. Incara's catalytic antioxidants have been shown to reduce damage to tissue in animal studies of neurological disorders such as amyotrophic lateral sclerosis (Lou Gehrig's disease) and stroke, and in other non-neurological indications such as cancer radiation therapy, chronic bronchitis and asthma. Incara has completed pharmacology studies, selected a first indication for clinical development, conducted preliminary dose ranging toxicology studies and completed scale-up synthesis of its lead molecule.

The statements in this press release that are not purely statements of historical fact are forward-looking statements, and actual results might differ materially from those anticipated. These statements and other statements made elsewhere by Incara or its representatives, which are identified or qualified by words such as "intends," "likely," "will," "suggests," "expects," "might," "may," "believe," "could," "should," "would," "anticipates," "plans," or the negative of those terms or similar expressions, are based on a number of assumptions that are subject to risks and uncertainties. Important factors that could cause results to differ include risks associated with the need to conserve and obtain funds for operations, and the uncertainties of clinical trials, product development activities and scientific research. These and other important risks are described in Incara's reports on Form 10-K, Form 10-Q and Form 8-K and its registration statements filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Incara assumes no obligation to update the information in this release.

SOURCE Incara Pharmaceuticals Corporation